(P018) Accelerated Partial Breast Radiotherapy Using VMAT-A Preliminary Dosimetric Comparison to Single-Entry Brachytherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

VMAT planning for the delivery of APBI in this preliminary dosimetric evaluation has been shown to be a viable option for APBI. VMAT planning gives acceptable lung and heart doses and appears to deliver lower doses to the heart and ipsilateral lung than APBI delivered with the single-entry SAVI applicator.

Yucel Saglam, Yasemin Bolukbasi, Steve Kirsner,Vildan Alpan, Duygu Sezen, Ugur Selek; American Hospital, MD Anderson Radiation Treatment Center, Istanbul; Department of Radiation Oncology, UT MD Anderson Cancer Center; Department of Radiation Oncology, Koc University

PURPOSE: To compare the dosimetric aspects of accelerated partial breast irradiation (APBI) with a single-entry brachytherapy device, strut-adjusted volumetric (SAVI), and external APBI using volumetric arc therapy (VMAT), with the intent of investigating the feasibility of using VMAT for the delivery of APBI treatments.

MATERIALS AND METHODS: Five left breast cancer patients who were planned and treated with SAVI at MD Anderson Cancer Center in Istanbul at American Hospital were randomly and retrospectively chosen from a database for this preliminary study. All patients were staged with T1N0M0 invasive breast cancer after partial mastectomy and sentinel lymph node dissection. The age of the patients ranged from 50 to 82 years. None of the patients received chemotherapy. The average cavity size was 12.6 mm (range: 2.2–18 mm), and all patients had invasive ductal carcinoma.

The plans and their contours were sent from the Oncentra Treatment Planning System to the Philips Pinnacle treatment planning system for replanning. VMAT APBI treatment plans were run on these same patients using the same contours delineated in the Oncentra planning system. The target volumes and planning parameters were set according to the National Surgical Adjuvant Breast and Bowel Project (NSABP)-39 protocol for external beam APBI, with a prescription dose of 38.5 Gy in 10 fractions. Dosimetric criteria on the heart and ipsilateral lung were used to compare the two techniques. Paired two-tailed Student’s t-test was performed to assess the differences in lung mean dose, heart mean dose, V20, V10, and V5 (%).

RESULTS: Even VMAT resulted in a decreased low-dose volume of the lung (V5: 0.1% vs 12.2%; P = .03); mean dose (204.1 cGy vs 287.2 cGy; P = .08), and V10 (0.02% vs 2.83%; P = .132) and V20 (0.001% vs 4.540%; P = .063) percentages of the lung were found to be similar. The difference in heart mean dose (243.6 cGy vs 342.8 cGy; P = .022) was influenced by the significant difference of heart V5 (0.083% vs 21.4%; P = .004), but the V20 (0.0001% vs 0.126%; P = .374) and V10 (0.008% vs 3.448%; P = .104) values of the heart were found to be comparable between the two techniques.

CONCLUSION: VMAT planning for the delivery of APBI in this preliminary dosimetric evaluation has been shown to be a viable option for APBI. VMAT planning gives acceptable lung and heart doses and appears to deliver lower doses to the heart and ipsilateral lung than APBI delivered with the single-entry SAVI applicator.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content